Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT05762133 Active, not recruiting - Clinical trials for Maternal Perinatal Depression

African-American Social Support Effectiveness Treatment

ASSET-PPD
Start date: August 27, 2020
Phase: N/A
Study type: Interventional

The objective of this treatment study is to develop and test an augmentation therapy in conjunction with maternal psychiatric treatment that targets the fathers' support of the mothers' mental health and contributions to the family environment to reduce maternal stress. The African-American Social Support Effectiveness Treatment-Partners alleviating Perinatal Depression (ASSET-PPD) intervention will be delivered to fathers in an individual setting to target the context in which a mother lives to expand her support beyond the direct reach of her treatment professional. This study provides skills and training to fathers who have a partner with prenatal depression. The aim is to reduce maternal depression during the perinatal period and improve the family environment for the infant.

NCT ID: NCT05738967 Active, not recruiting - Depression Clinical Trials

Transdiagnostic Behavioral Therapy for Anxiety and Depression in Autistic Adolescents

Start date: March 15, 2023
Phase: N/A
Study type: Interventional

This study tests the effectiveness of a transdiagnostic cognitive behavioral therapy for autistic youth with anxiety and/or depression.

NCT ID: NCT05698394 Active, not recruiting - Clinical trials for Postpartum Depression

Effect of Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth

Start date: June 19, 2020
Phase: Phase 4
Study type: Interventional

Postpartum depression refers to the depression after childbirth, which is a common mental disorder in women. The pathogenesis of postpartum depression is not fully understood, and may be related to a variety of factors. Prenatal depression is an important risk factor for postpartum depression. Our recent multicenter randomized controlled trial, "Effect of Low-dose esketamine on the incidence of postpartum depression in women with prenatal depression", explored the effect of immediate postpartum intravenous infusion of low-dose esketamine on the incidence of postpartum depression in women with prenatal depression. The preliminary results showed that it reduced the incidence of postpartum depression at 42 days. Since there were no studies on the effect of intravenous esketamine infusion after delivery on long-term postpartum depression, this study is a long-term follow-up of the previous randomized trial. We aim to explore the effect of low-dose intravenous esketamine after delivery on the incidence of 2-year maternal depression after delivery in women with prenatal depressive symptoms.

NCT ID: NCT05697172 Active, not recruiting - Clinical trials for Major Depressive Disorder

Low Intensity Ultrasound Neuromodulation of Repetitive Negative Thinking In Depression

Start date: December 15, 2022
Phase: N/A
Study type: Interventional

The investigators propose to use low-intensity transcranial focused ultrasound (LIFU), a novel neuromodulation method, to probe the causal involvement of individually defined components of an anteromedial brain circuit in the processing of self-referential thoughts, and the production of repetitive negative thinking (RNT), a prominent transdiagnostic manifestation with adverse clinical consequences. The investigators hypothesize that real vs. sham low-intensity sonication of individually-defined anteromedial structures connecting medial orbitofrontal and anterior cingulate cortices with ventral striatum and anterior thalamus will show reduced initiation or maintenance of RNT as measured by (1) Brief State Rumination Inventory (BSRI) scores and distress associated to repetitive negative thoughts, and (2) improvement of the affective valence associated to self-referential adjectives, and that these changes will be associated with decreased connectivity between structures mentioned above. The present early feasibility study is an initial step that aims to determine its feasibility and help with the planning of a larger study addressed at actual hypothesis testing.

NCT ID: NCT05657691 Active, not recruiting - Clinical trials for Major Depressive Disorder

Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

Start date: November 28, 2022
Phase: Phase 2
Study type: Interventional

Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamemâ„¢ in treating patients with cognitive and depressive symptoms. Trial participants will be randomized to either receive 10mg of Xanamemâ„¢ once daily or a Placebo at a 1:1 ratio in a double-blinded fashion.

NCT ID: NCT05632510 Active, not recruiting - Clinical trials for Peripartum Depression (PPD)

PREVENTION OF PERINATAL DEPRESSION BY EPDS DURING THE FIRST PRENATAL CONSULTATION AT MATERNITY DEPARTMENT

PREVIDEPP
Start date: October 21, 2022
Phase: N/A
Study type: Interventional

The risk of PPD for a woman giving birth ranges between 10 and 20% worldwide, with about a third of postpartum depression that begin during pregnancy. PPD has been associated to negative short-/long-term effects for the mother's health, the child's health and early interactions when left untreated. PPD is underdiagnosed, less than half of patients being diagnosed partly because of atypical symptoms, reluctance of patients to seek help, and because of the lack of systematic screening for this condition. Other specific biological changes could also be involved. Reduction in plasma oxytocin levels have been shown to be associated with the risk of PPD and heritability studies have identified a genetic contribution. The Edinburgh Postnatal Depression Scale (EPDS) is a self-administered questionnaire of 10 items, is recommended by the NICE guideline and French National Authority for Health for screening peripartum women, validated in French and well accepted. In France, the first contact with midwives or obstetricians during pregnancy usually occurs around the 4th month of pregnancy. French National Authority for Health recommends evaluation of risk factors for depression during this first consultation. However, this interview is rarely done probably because assessment of depression could be considered as difficult and time consuming. However, a meta-analysis shows that screening depression in the general population significantly reduces the risk for persistent depression (relative risk 0.87 [95%CI 0.79 to 0.95]), as compared to usual care. Our hypothesis is that early identification of vulnerability/depression in pregnant women would enable clinical team to offer adequate psychological and psychosocial care during pregnancy, thus reducing PPD in these women. The investigators propose to assess the impact of a systematic screening of depression using EPDS during an early consultation in comparison with usual practices, on the risk of depression during peripartum period (PPD).

NCT ID: NCT05601362 Active, not recruiting - Depression Clinical Trials

Evaluation of a Therapeutic Mobile App for Depression

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is a preliminary evaluation of a gamified attention bias modification training (GAMBT) for reducing symptoms of depression and rumination. Individuals with elevated symptoms of depression will use the digital intervention over the course of 4 weeks. They will complete a brief (~5 question) survey daily, as well as weekly assessments.

NCT ID: NCT05574491 Active, not recruiting - Anxiety Disorders Clinical Trials

Effectiveness of Traditional and Computerized Versions of Super Skills for Life in Children

Start date: February 7, 2023
Phase: N/A
Study type: Interventional

Super Skills for Life (SSL) is a transdiagnostic cognitive-behavioral protocol developed for children aged 6 to 12 with anxiety and comorbid problems (e.g., depression, low self-esteem, and lack of social skills). SSL consists of eight sessions targeting common risk factors for internalizing disorders such as cognitive distortions, avoidance, emotional management, low self-esteem, social skills deficits and coping strategies. The aim of the study is to investigate the comparative effectiveness of SSL in its traditional and computerized versions on internalizing symptoms in Spanish children between 8 and 12 years of age.

NCT ID: NCT05551702 Active, not recruiting - Moderate Depression Clinical Trials

Treating Depression With Text Messaging

Start date: July 6, 2022
Phase: N/A
Study type: Interventional

The purpose of the research study is to investigate whether CBT-txt, a counseling program delivered by text messages is effective in stopping or reducing depressive symptoms. CBT-txt is based on a counseling program that has been proven to reduce depression when delivered in-person and on the web, but has not yet been tested or shown to be effective when delivered by text.

NCT ID: NCT05543265 Active, not recruiting - Obesity Clinical Trials

Bridging the Gap From Postpartum to Primary Care

Start date: November 3, 2022
Phase: N/A
Study type: Interventional

Chronic health conditions affect most older adults. Preventative medicine and risk management strategies, especially when applied earlier in life, are essential to altering the trajectory of a disease and ultimately improving health outcomes. Primary care providers (PCP) often provide most of these services, though younger adults are the least likely to receive primary care. This project leverages a period of high engagement and health activation during an individual's life (pregnancy) to nudge her toward use of primary care after the pregnancy episode. This randomized controlled trial will test the hypothesis that a behavioral science-informed intervention, incorporating defaults and salience, can increase the rates of PCP follow-up within 4 months following a delivery for individual with hypertension, diabetes, obesity. If successful, this intervention could serve as a scalable solution to increase primary care use and preventative health services in a population that currently has low rates of engagement and utilization of these services.